Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients
Open Access
- 17 March 2009
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 100 (6) , 870-873
- https://doi.org/10.1038/sj.bjc.6604971
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Twenty Novel Genetic Variations and Haplotype Structures of the DCK Gene Encoding Human Deoxycytidine Kinase (dCK)Drug Metabolism and Pharmacokinetics, 2008
- Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic VariantsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?British Journal of Cancer, 2007
- Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase PolymorphismJournal of Clinical Oncology, 2007
- Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus CisplatinClinical Cancer Research, 2005
- Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathwayThe Pharmacogenomics Journal, 2004
- GemcitabineDrugs, 1997
- Preclinical characteristics of gemcitabineAnti-Cancer Drugs, 1995